Ensysce Biosciences Inc (ENSC)

$0.61 +0.06 (11.44%)
Market Cap 2.21M
Revenue (ttm) 5.21M
Net Income (ttm) -7.99M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin -153.36%
Debt to Equity Ratio 0.00
Volume 233,300
Avg Vol 7,432,712
Day's Range N/A - N/A
Shares Out 3.63M
Stochastic %K 100%
Beta 1.12
Analysts Strong Buy
Price Target $16.45

Company Profile

Ensysce Biosciences, Inc., a clinical-stage pharmaceutical company, develops prescription drugs for severe pain relief in opioid misuse, abuse, and overdose in the United States. It develops products using Trypsin Activated Abuse Protection (TAAP) platform, designed to release clinically effective drugs only when exposed to specific physiological conditions; and Multi-Pill Abuse Resistance (MPAR) platform, an over-dose protection opioid prodrug technology. The company's lead product candidate is...

Industry: Biotechnology
Sector: Healthcare
Phone: 858 263 4196
Address:
7946 Ivanhoe Avenue, Suite 201, La Jolla, United States
Wallstreetiscriminal
Wallstreetiscriminal Apr. 3 at 5:14 PM
$ENSC @ Sauna Timo, but other than that it’s a great investment! Maybe I’ll buy more! Lol
1 · Reply
Tradefun1979
Tradefun1979 Apr. 3 at 3:10 PM
$ENSC The last rs was way before last 52 weeks high I, if I am not wrong., last rs 1:15 Dec 24, then 52vweks high 4.85 April 25, so the company is just decimated since last rs. This has to really do something to show to investors.
0 · Reply
Wallstreetiscriminal
Wallstreetiscriminal Apr. 3 at 2:48 PM
$ENSC You’re missing their annual RS where they RS three years straight whittling shareholders shares down to nothing and scaring potential investors away by doing so. There should be a law that those shares get returned to shareholders if the company hits certain $ milestones should they become successful! Instead they benefit and we eat sh*t.
1 · Reply
ToTheSauna
ToTheSauna Apr. 3 at 1:49 PM
$ENSC I just came across this biotech. I understand funding is tight, but I don't think I've ever seen a Phase 3-stage company with a market cap of only ~$5-6 million before. They also have other pipeline candidates. Why is the valuation this low? What am I missing?
2 · Reply
Tradefun1979
Tradefun1979 Apr. 3 at 12:57 PM
$ENSC Duddest of micropenny stocks.
0 · Reply
SonGoku81
SonGoku81 Apr. 2 at 9:54 PM
@SqueezeSharkie has been calling out some serious bangers lately. Definitely worth a Follow. Solid trader in my opinion, and I’ve personally made some nice gains from his picks. $BKSY $ENSC $ORIS >> on watch!!
1 · Reply
beestMod516
beestMod516 Apr. 2 at 9:50 PM
$ENSC I am new here. What’s the story ?
0 · Reply
fromtheothersid3
fromtheothersid3 Apr. 2 at 9:25 PM
$ENGS one hell of a Beauty ☺️❤️ Just as $ENSC Also $PHIO My Favorits... All of Them.. Nr 1 might be $ENSC wich is my largest Position. But the other two are not far behind size wise ☺️❤️
0 · Reply
fromtheothersid3
fromtheothersid3 Apr. 2 at 9:12 PM
$ENSC Beauty ☺️
0 · Reply
DILF32
DILF32 Apr. 2 at 8:31 PM
$ENSC
0 · Reply
Latest News on ENSC
Ensysce Biosciences Reports Fourth Quarter and Full Year 2025 Financial Results

Mar 30, 2026, 4:50 PM EDT - 5 days ago

Ensysce Biosciences Reports Fourth Quarter and Full Year 2025 Financial Results

Ensysce Biosciences Initiates Live "Ask Me Anything" (AMA) Session Highlighting Growth and Future Plans

Mar 4, 2026, 8:45 AM EST - 4 weeks ago

Ensysce Biosciences Initiates Live "Ask Me Anything" (AMA) Session Highlighting Growth and Future Plans

Ensysce Biosciences Announces First Peer-Reviewed Clinical Publication Demonstrating Oral Overdose Protection with MPAR(R) Technology

Mar 3, 2026, 8:00 AM EST - 4 weeks ago

Ensysce Biosciences Announces First Peer-Reviewed Clinical Publication Demonstrating Oral Overdose Protection with MPAR(R) Technology

Tiny Pain-Focused Biotech Ensysce Biosciences Surges Amid Strategic Review

Feb 27, 2026, 12:10 PM EST - 5 weeks ago

Tiny Pain-Focused Biotech Ensysce Biosciences Surges Amid Strategic Review

Ensysce Biosciences Initiates Review of Strategic Alternatives to Enhance Shareholder Value

Feb 25, 2026, 8:00 AM EST - 5 weeks ago

Ensysce Biosciences Initiates Review of Strategic Alternatives to Enhance Shareholder Value

Ensysce Biosciences Invited to Participate in Upcoming Scientific and Industry Events

Feb 23, 2026, 8:00 AM EST - 5 weeks ago

Ensysce Biosciences Invited to Participate in Upcoming Scientific and Industry Events

Ensysce Biosciences Provides Enrollment Update on Pivotal Phase 3 Trial of PF614, Its Next-Generation Opioid for Severe Acute Pain

Jan 28, 2026, 8:00 AM EST - 2 months ago

Ensysce Biosciences Provides Enrollment Update on Pivotal Phase 3 Trial of PF614, Its Next-Generation Opioid for Severe Acute Pain

Ensysce Biosciences Expands Global Opioid Patent Portfolio

Jan 21, 2026, 8:00 AM EST - 2 months ago

Ensysce Biosciences Expands Global Opioid Patent Portfolio

Ensysce Biosciences Receives EU Patent Expanding its First-in-Class ADHD Therapy with Built-In Abuse and Overdose Protection

Jan 8, 2026, 8:00 AM EST - 3 months ago

Ensysce Biosciences Receives EU Patent Expanding its First-in-Class ADHD Therapy with Built-In Abuse and Overdose Protection

Ensysce Biosciences Issues Annual Shareholder Letter

Jan 5, 2026, 8:00 AM EST - 3 months ago

Ensysce Biosciences Issues Annual Shareholder Letter

Diamond Equity Research Releases Update Note on Ensysce Biosciences, Inc. (NASDAQ: ENSC)

Dec 12, 2025, 8:00 AM EST - 4 months ago

Diamond Equity Research Releases Update Note on Ensysce Biosciences, Inc. (NASDAQ: ENSC)

Ensysce Biosciences Achieves Major Milestone with Initiation of Enrollment in Pivotal Phase 3 Trial of PF614, Its Next-Generation Opioid

Dec 9, 2025, 8:00 AM EST - 4 months ago

Ensysce Biosciences Achieves Major Milestone with Initiation of Enrollment in Pivotal Phase 3 Trial of PF614, Its Next-Generation Opioid

Ensysce Biosciences Announces Broader Patent Protection for Groundbreaking MPAR(R) Overdose Protection Technology

Dec 2, 2025, 8:00 AM EST - 4 months ago

Ensysce Biosciences Announces Broader Patent Protection for Groundbreaking MPAR(R) Overdose Protection Technology

Ensysce Biosciences Receives Positive FDA Feedback on PF614 Manufacturing Approach

Nov 20, 2025, 8:00 AM EST - 4 months ago

Ensysce Biosciences Receives Positive FDA Feedback on PF614 Manufacturing Approach

Ensysce Biosciences Secures $4 Million Financing, Unlocking Up to $20 Million in Total Financing to Advance Breakthrough Pain Programs

Nov 17, 2025, 8:05 AM EST - 4 months ago

Ensysce Biosciences Secures $4 Million Financing, Unlocking Up to $20 Million in Total Financing to Advance Breakthrough Pain Programs

Ensysce Biosciences Reports Third Quarter 2025 Financial Results

Nov 14, 2025, 4:15 PM EST - 5 months ago

Ensysce Biosciences Reports Third Quarter 2025 Financial Results

Ensysce Biosciences Releases Symposium Highlights from PAINWeek 2025

Oct 10, 2025, 8:00 AM EDT - 6 months ago

Ensysce Biosciences Releases Symposium Highlights from PAINWeek 2025

Ensysce Biosciences Showcases Urgent Need for Safer Opioids at PAINWeek 2025 Symposium

Sep 4, 2025, 8:00 AM EDT - 7 months ago

Ensysce Biosciences Showcases Urgent Need for Safer Opioids at PAINWeek 2025 Symposium

Ensysce Biosciences' Geoff Birkett to Chair the Fierce New Product Planning Summit 2025

Aug 19, 2025, 8:00 AM EDT - 8 months ago

Ensysce Biosciences' Geoff Birkett to Chair the Fierce New Product Planning Summit 2025

Ensysce Biosciences Reports Second Quarter 2025 Financial Results and Latest Program Updates

Aug 13, 2025, 4:15 PM EDT - 8 months ago

Ensysce Biosciences Reports Second Quarter 2025 Financial Results and Latest Program Updates

Ensysce Biosciences Advances Breakthrough Opioid With Built-In Overdose Protection Following Positive FDA Feedback

Jul 31, 2025, 8:00 AM EDT - 8 months ago

Ensysce Biosciences Advances Breakthrough Opioid With Built-In Overdose Protection Following Positive FDA Feedback

Ensysce Biosciences Initiates Pivotal Phase 3 Study of PF614 - A Next-Generation Opioid - Designed to Deliver Powerful Pain Relief and Reduce Abuse

Jul 16, 2025, 8:00 AM EDT - 9 months ago

Ensysce Biosciences Initiates Pivotal Phase 3 Study of PF614 - A Next-Generation Opioid - Designed to Deliver Powerful Pain Relief and Reduce Abuse

Ensysce Biosciences Accelerates PF614-MPAR-102 Study with Full Enrollment of Part 2

Jun 24, 2025, 8:00 AM EDT - 10 months ago

Ensysce Biosciences Accelerates PF614-MPAR-102 Study with Full Enrollment of Part 2

Ensysce Biosciences Announces Speakers for Major Symposium at PAINWeek 2025

Jun 11, 2025, 8:00 AM EDT - 10 months ago

Ensysce Biosciences Announces Speakers for Major Symposium at PAINWeek 2025

Ensysce Biosciences Awarded $5.3 Million in Continued NIDA Support to Advance Breakthrough Opioid Overdose Protection

Jun 4, 2025, 8:00 AM EDT - 10 months ago

Ensysce Biosciences Awarded $5.3 Million in Continued NIDA Support to Advance Breakthrough Opioid Overdose Protection

Ensysce Biosciences Reports First Quarter 2025 Financial Results

May 13, 2025, 4:15 PM EDT - 11 months ago

Ensysce Biosciences Reports First Quarter 2025 Financial Results

Ensysce Biosciences Bolsters Management Team with Regulatory Expert

May 12, 2025, 8:00 AM EDT - 11 months ago

Ensysce Biosciences Bolsters Management Team with Regulatory Expert

Ensysce Biosciences, Inc. Announces Closing of Exercise of Warrants for $2.2 Million Gross Proceeds

Apr 24, 2025, 4:15 PM EDT - 1 year ago

Ensysce Biosciences, Inc. Announces Closing of Exercise of Warrants for $2.2 Million Gross Proceeds

Ensysce Biosciences Stock Doubles In One Trading Session - Here's Why

Apr 23, 2025, 5:11 PM EDT - 1 year ago

Ensysce Biosciences Stock Doubles In One Trading Session - Here's Why

Ensysce Biosciences, Inc. Announces Exercise of Warrants for $2.2 Million Gross Proceeds

Apr 23, 2025, 4:41 PM EDT - 1 year ago

Ensysce Biosciences, Inc. Announces Exercise of Warrants for $2.2 Million Gross Proceeds

Ensysce Biosciences Receives U.S. Patent for Groundbreaking Treatment of Opioid Use Disorder

Apr 23, 2025, 8:00 AM EDT - 1 year ago

Ensysce Biosciences Receives U.S. Patent for Groundbreaking Treatment of Opioid Use Disorder

Ensysce Biosciences Announces Positive Data from Opioid Overdose Protection Study

Apr 15, 2025, 8:00 AM EDT - 1 year ago

Ensysce Biosciences Announces Positive Data from Opioid Overdose Protection Study

Ensysce Biosciences, Inc. Announces $1.1 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules

Mar 31, 2025, 8:00 AM EDT - 1 year ago

Ensysce Biosciences, Inc. Announces $1.1 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules

Ensysce Biosciences Announces PAINWeek 2025 Symposium and Recent Expert Panel Discussion on The State of the Nation in Pain

Mar 18, 2025, 8:00 AM EDT - 1 year ago

Ensysce Biosciences Announces PAINWeek 2025 Symposium and Recent Expert Panel Discussion on The State of the Nation in Pain

Ensysce Biosciences Reports Fourth Quarter and Full Year 2024 Financial Results

Mar 10, 2025, 4:15 PM EDT - 1 year ago

Ensysce Biosciences Reports Fourth Quarter and Full Year 2024 Financial Results

Ensysce Biosciences to Participate in the 37th Annual ROTH Conference

Mar 5, 2025, 8:00 AM EST - 1 year ago

Ensysce Biosciences to Participate in the 37th Annual ROTH Conference

Ensysce Biosciences CEO Dr. Lynn Kirkpatrick and Creighton University's Dr. Neel Pathak Discuss the Opioid Crisis and Next Generation Opioids

Mar 3, 2025, 9:43 AM EST - 1 year ago

Ensysce Biosciences CEO Dr. Lynn Kirkpatrick and Creighton University's Dr. Neel Pathak Discuss the Opioid Crisis and Next Generation Opioids

Ensysce Biosciences Reports Continued Positive Progress in Groundbreaking Trial on PF614-MPAR, Comments on Current Landscape for Pain Treatment

Feb 5, 2025, 8:00 AM EST - 1 year ago

Ensysce Biosciences Reports Continued Positive Progress in Groundbreaking Trial on PF614-MPAR, Comments on Current Landscape for Pain Treatment

Ensysce Biosciences Announces Positive Interim Data for Breakthrough Therapy PF614-MPAR

Jan 22, 2025, 8:00 AM EST - 1 year ago

Ensysce Biosciences Announces Positive Interim Data for Breakthrough Therapy PF614-MPAR

Ensysce Biosciences Regains Full Compliance with Nasdaq

Dec 23, 2024, 8:00 AM EST - 1 year ago

Ensysce Biosciences Regains Full Compliance with Nasdaq

Ensysce Biosciences Announces Commercial Supplier for Breakthrough Overdose Protection Drug Product

Dec 10, 2024, 8:00 AM EST - 1 year ago

Ensysce Biosciences Announces Commercial Supplier for Breakthrough Overdose Protection Drug Product

Ensysce Biosciences Announces Strategic Partnership for the Development and Commercial Launch of PF614 and PF614-MPAR

Dec 4, 2024, 8:00 AM EST - 1 year ago

Ensysce Biosciences Announces Strategic Partnership for the Development and Commercial Launch of PF614 and PF614-MPAR

Ensysce Biosciences Announces 1-for-15 Reverse Stock Split

Dec 3, 2024, 4:15 PM EST - 1 year ago

Ensysce Biosciences Announces 1-for-15 Reverse Stock Split

Ensysce Biosciences Completes Significant Milestone, Dosing First Subjects in Breakthrough Therapy PF614-MPAR Trial

Nov 26, 2024, 8:00 AM EST - 1 year ago

Ensysce Biosciences Completes Significant Milestone, Dosing First Subjects in Breakthrough Therapy PF614-MPAR Trial

Ensysce Biosciences Reports Third Quarter 2024 Financial Results

Nov 12, 2024, 4:15 PM EST - 1 year ago

Ensysce Biosciences Reports Third Quarter 2024 Financial Results

Ensysce Biosciences Receives Positive Nasdaq Listing Determination

Nov 7, 2024, 8:00 AM EST - 1 year ago

Ensysce Biosciences Receives Positive Nasdaq Listing Determination

Ensysce Biosciences Announces Leadership Team's Participation in the Annual Pain Therapeutics Summit

Oct 8, 2024, 8:00 AM EDT - 1 year ago

Ensysce Biosciences Announces Leadership Team's Participation in the Annual Pain Therapeutics Summit

Ensysce Biosciences Provides Shareholder Update, Responds to Recent Shareholder Inquiries

Oct 2, 2024, 8:00 AM EDT - 1 year ago

Ensysce Biosciences Provides Shareholder Update, Responds to Recent Shareholder Inquiries

Ensysce Biosciences Receives Notice from Nasdaq

Sep 27, 2024, 4:30 PM EDT - 1 year ago

Ensysce Biosciences Receives Notice from Nasdaq

Ensysce Biosciences Presenting at Upcoming Meetings

Sep 24, 2024, 8:00 AM EDT - 1 year ago

Ensysce Biosciences Presenting at Upcoming Meetings

Wallstreetiscriminal
Wallstreetiscriminal Apr. 3 at 5:14 PM
$ENSC @ Sauna Timo, but other than that it’s a great investment! Maybe I’ll buy more! Lol
1 · Reply
Tradefun1979
Tradefun1979 Apr. 3 at 3:10 PM
$ENSC The last rs was way before last 52 weeks high I, if I am not wrong., last rs 1:15 Dec 24, then 52vweks high 4.85 April 25, so the company is just decimated since last rs. This has to really do something to show to investors.
0 · Reply
Wallstreetiscriminal
Wallstreetiscriminal Apr. 3 at 2:48 PM
$ENSC You’re missing their annual RS where they RS three years straight whittling shareholders shares down to nothing and scaring potential investors away by doing so. There should be a law that those shares get returned to shareholders if the company hits certain $ milestones should they become successful! Instead they benefit and we eat sh*t.
1 · Reply
ToTheSauna
ToTheSauna Apr. 3 at 1:49 PM
$ENSC I just came across this biotech. I understand funding is tight, but I don't think I've ever seen a Phase 3-stage company with a market cap of only ~$5-6 million before. They also have other pipeline candidates. Why is the valuation this low? What am I missing?
2 · Reply
Tradefun1979
Tradefun1979 Apr. 3 at 12:57 PM
$ENSC Duddest of micropenny stocks.
0 · Reply
SonGoku81
SonGoku81 Apr. 2 at 9:54 PM
@SqueezeSharkie has been calling out some serious bangers lately. Definitely worth a Follow. Solid trader in my opinion, and I’ve personally made some nice gains from his picks. $BKSY $ENSC $ORIS >> on watch!!
1 · Reply
beestMod516
beestMod516 Apr. 2 at 9:50 PM
$ENSC I am new here. What’s the story ?
0 · Reply
fromtheothersid3
fromtheothersid3 Apr. 2 at 9:25 PM
$ENGS one hell of a Beauty ☺️❤️ Just as $ENSC Also $PHIO My Favorits... All of Them.. Nr 1 might be $ENSC wich is my largest Position. But the other two are not far behind size wise ☺️❤️
0 · Reply
fromtheothersid3
fromtheothersid3 Apr. 2 at 9:12 PM
$ENSC Beauty ☺️
0 · Reply
DILF32
DILF32 Apr. 2 at 8:31 PM
$ENSC
0 · Reply
fromtheothersid3
fromtheothersid3 Apr. 2 at 8:30 PM
$ENSC can't wait for 0,80 Break ☺️ I am a Fan of No Gap.. but If we move wild one day ah/PM/next day... I Take it ❤️
0 · Reply
LosersMakeMillions
LosersMakeMillions Apr. 2 at 8:22 PM
$ENSC
1 · Reply
fromtheothersid3
fromtheothersid3 Apr. 2 at 8:21 PM
$ENSC After hours moving some... Ask Above 0,67 right now ☺️
0 · Reply
fromtheothersid3
fromtheothersid3 Apr. 2 at 8:15 PM
$ENSC every cent is 500$ for me Both direction indeed 😆☺️
0 · Reply
fromtheothersid3
fromtheothersid3 Apr. 2 at 8:08 PM
$ENSC very soon to Blow imho Company does know how to Play this one Also with real News Great Pipeline But for a Trader the squeeeezeee is in Play ☺️🤘🏽
0 · Reply
fromtheothersid3
fromtheothersid3 Apr. 2 at 7:56 PM
$ENSC setting up now... Again :
0 · Reply
Sunnybhargava
Sunnybhargava Apr. 2 at 7:55 PM
$ENSC looks like some good news coming soon 🚀
0 · Reply
fromtheothersid3
fromtheothersid3 Apr. 2 at 7:50 PM
$ENSC what is an OS of 9,5 Million?!?! Nothing !!! They Play it well... In the interest of shareholders Pump companys would do 500 Million OS ☺️🤘🏽
1 · Reply
fromtheothersid3
fromtheothersid3 Apr. 2 at 7:45 PM
$ENSC ask extremely thin ☺️👌🏽
0 · Reply
Annet_why_net
Annet_why_net Apr. 2 at 7:44 PM
$ENSC 😏
0 · Reply
Big_Zack22
Big_Zack22 Apr. 2 at 7:39 PM
$ENSC
0 · Reply
fromtheothersid3
fromtheothersid3 Apr. 2 at 7:38 PM
$ENSC Not the big Boom yet... But getting there ☺️
0 · Reply